REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC NSCLC AFTER RECEIVING FIRST-LINE PEMBROLIZUMAB WITH PEMETREXED/PLATINUM CHEMOTHERAPY IN THE US ONCOLOGY NETWORK

被引：0
|
作者：
Goldschmidt, Jerome [1 ]
Annavarapu, Srinivas [2 ]
Venkatasetty, Divea [2 ]
Santorelli, Melissa [3 ]
Burke, Thomas [3 ]
Pennell, Nathan [4 ]
机构：
[1] US Oncol Network, Blacksburg, VA USA
[2] Ontada, Irving, TX USA
[3] Merck & Co Inc, Rahway, NJ 07065 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
933
引用
收藏
页码：A974 / A975
页数：2
相关论文
共 50 条
  • [1] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
    Vamsidhar Velcheti
    Xiaohan Hu
    Bilal Piperdi
    Thomas Burke
    Scientific Reports, 11
  • [2] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Burke, Thomas
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] Real-World US Treatment Patterns and Clinical Outcomes in Advanced NSCLC After Prior Platinum Chemotherapy and Immunotherapy
    Smith, T.
    Knoll, S.
    Martinalbo, J.
    Ye, F.
    Kolaei, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1001 - S1001
  • [4] First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
    Liu, S.
    Rai, P.
    Wang, D.
    Hu, X.
    Schwarzenberger, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S383 - S384
  • [5] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
    Russano, M.
    Cantini, L.
    B, A. P.
    George, R.
    Nunes, P.
    Tolba, K.
    Dutra, C.
    Chico, I.
    Cortellini, A.
    Pecci, F.
    Alessi, J. V.
    Ricciuti, B.
    Ramkissoon, S.
    Aerts, J. G.
    Agrawal, S.
    Saini, K. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854
  • [6] Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US
    Chopra, D.
    Waterhouse, D. M.
    Sultan, I.
    Lonshteyn, A.
    Delea, T. E.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S400 - S401
  • [7] Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*
    Miyamoto, Toshihiro
    Sanford, David
    Tomuleasa, Ciprian
    Hsiao, Hui-Hua
    Enciso Olivera, Leonardo Jose
    Kumar Enjeti, Anoop
    Gimenez Conca, Alberto
    Bernal Del Castillo, Teresa
    Girshova, Larisa
    Paola Martelli, Maria
    Guvenc, Birol
    Delgado, Alexander
    Duan, Yinghui
    Garbayo Guijarro, Belen
    Llamas, Cynthia
    Lee, Je-Hwan
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 928 - 938
  • [8] First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
    Liu, Stephen V.
    Rai, Pragya
    Wang, Dong
    Hu, Xiaohan
    Schwarzenberger, Paul Otto
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [9] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
  • [10] US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
    Bittoni, M. A.
    Divan, H. A.
    Krishna, A.
    Gosset, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1416 - S1416
12345